1. Home
  2. SA vs KOD Comparison

SA vs KOD Comparison

Compare SA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seabridge Gold Inc. (Canada)

SA

Seabridge Gold Inc. (Canada)

HOLD

Current Price

$25.71

Market Cap

2.8B

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$41.98

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SA
KOD
Founded
1979
2009
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.3B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
SA
KOD
Price
$25.71
$41.98
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$65.00
$35.43
AVG Volume (30 Days)
607.0K
858.4K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.11
$4.60
52 Week High
$40.06
$47.84

Technical Indicators

Market Signals
Indicator
SA
KOD
Relative Strength Index (RSI) 44.10 61.86
Support Level $24.09 $39.37
Resistance Level $32.47 $46.72
Average True Range (ATR) 1.35 3.19
MACD 0.03 0.63
Stochastic Oscillator 34.89 80.61

Price Performance

Historical Comparison
SA
KOD

About SA Seabridge Gold Inc. (Canada)

Seabridge Gold Inc is a development-stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: